Cas:77354-98-4 2-[4-(2-formylphenoxy)butoxy]benzaldehyde manufacturer & supplier

Chemical Name:2-[4-(2-formylphenoxy)butoxy]benzaldehyde

CAS.NO:77354-98-4

Synonyms:2-[4-(2-formylphenoxy)butoxy]benzaldehyde

Molecular Formula:C₁₈H₁₈O₄

Molecular Weight:298.33300

HS Code:2912299000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:52.60000

Exact Mass:298.12100

LogP:3.54960

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-[4-(2-formylphenoxy)butoxy]benzaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-[4-(2-formylphenoxy)butoxy]benzaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-[4-(2-formylphenoxy)butoxy]benzaldehyde Use and application,2-[4-(2-formylphenoxy)butoxy]benzaldehyde technical grade,usp/ep/jp grade.

Related News: As for the consumer health unit, GSK plans to demerge it by mid-2022, during which GSK will shed at least 80% of its 68% holding in the JV to shareholders. 4-chloro-3-(methylsulfamoyl)benzoic acid manufacturers So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off. 3-amino-2-propan-2-ylquinazolin-4-one suppliers Contract research organisation Charles River Laboratories International Inc. today announced plans for an €8M expansion of its testing capabilities at its Ballina, Co. Mayo site that will give an additional 1,500m2 of lab space and create up to 90 new skilled roles over the next three years. N-methylphenylethanolamine vendor & factory Less than three weeks after unveiling the construction of a new fill-finish facility in Morocco, the Sweden-based company announced it was undergoing construction of another fill-finish plant in India.,As for the consumer health unit, GSK plans to demerge it by mid-2022, during which GSK will shed at least 80% of its 68% holding in the JV to shareholders.